Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status

Follicular Lymphoma Clinical Trial

— FLMRD  

Official title:

Adjustment of Chemotherapy Duration in Follicular Lymphoma Patients According to Peripheral Blood or Bone Marrow Minimal Residual Disease Status

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04934930
• Other study ID #: MMC-19-0209
• Status: Recruiting
• Phase: Phase 2
• Start date: January 29, 2020
• Est. completion date: August 1, 2025

Study information

• Verified date: June 2021
• Source: Meir Medical Center
• Contact: Uri Abadi, MD
• Phone: 972-9-7472786
• Email: uri.abadi[@]clalit.org.il
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Follicular lymphoma (FL) is a chronic indolent malignancy, where treatment with 6 cycles of bendamustine obinutuzumab (BO) is highly effective but at a cost of increased adverse events.

Tumor specific DNA can be traced in blood and bone marrow of follicular lymphoma patients even after therapy, and when detected after lymphoma treatment it is referred to as minimal residual disease (MRD).

MRD elimination after effective lymphoma treatment is a marker for deep response and correlates with prolonged remission.

In this study we aim to omit chemotherapy after 4 cycles of treatment in patients achieving MRD elimination after 3 months of therapy, as well as complete metabolic response on positron emission computed tomography (PET-CT), hoping to preserve treatment effectiveness while reducing adverse events.

Description:

Follicular lymphoma (FL) is the second most common type of non-Hodgkin's lymphoma, with an estimated incidence of 3.18 cases per 100000 people a year in the United States The disease is characterized by an indolent behavior, where often treatment is unnecessary at diagnosis, and a "watch & wait" approach is the standard of care for asymptomatic patients. FL is also a highly responsive disease for immuno-chemotherapeutic combinations, although most patients will eventually relapse. Since the disease is incurable & indolent in nature, the therapeutic strategy should aim for disease control, while using treatments with high safety profile in order to minimize the chance for life threatening adverse events.

Therapy with rituximab cyclophosphamide, doxorubicin, vincristine & prednisone (R-CHOP) combination & subsequent rituximab maintenance therapy for 24 months shows excellent results with a median progression free survival (PFS) of above a decade.

The more recent GALLIUM trial has shown that combining the monoclonal antibody obinutuzumab with chemotherapy is even more efficacious compared to rituximab combinations. When different combinations were examined in this trial the best results were achieved with the bendamustine-obinutuzumab (BO) combination with 3 year PFS of 84%. Unfortunately the trial also revealed a downside for this effective combination with higher rate of fatal adverse events among patients receiving 6 cycles of bendamustine combinations.

In patients with acute leukemia evaluation for minimal residual disease (MRD) is a routine procedure, and the nature & length of treatment are guided by MRD status at different time points during therapy.

Among FL patients treated with obinutuzumab-chemotherapy combinations, it has been shown that after 3 cycles of treatment about 90% of patients were MRD negative. In addition MRD negativity at the end of induction in either peripheral blood or bone marrow was found to be associated with improved outcomes in patients with 1st line treatment for FL as well as in the relapsed setting.

These findings raise the possibility for an MRD based treatment approach, where the duration of chemotherapy could be guided by MRD status at mid-induction. Eliminating chemotherapy while continuing immunotherapy after achievement of MRD negativity & complete metabolic remission on PET-CT at mid-induction could reduce treatment toxicity, while potentially preserving efficacy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: August 1, 2025
• Est. primary completion date: August 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age 18 and above.

2. FL grade I-IIIa, according to world health organization (WHO) classification, in patients who were not previously treated with chemotherapy, have a high tumor bulk & an indication for treatment, as defined by the Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria.

3. Eastern Cooperative Oncology Group (ECOG) performance status grade 0-2.

4. The presence of a molecular marker in bone marrow or peripheral blood for MRD assessment.

Exclusion Criteria:

1. FL grade IIIb.

2. HIV infection.

3. HBsAg positivity.

4. Active malignancy other than FL

5. Pregnancy or lactation.

Related Conditions & MeSH terms

• Follicular Lymphoma
• Lymphoma
• Lymphoma, Follicular
• Neoplasm, Residual

Intervention

Drug:
• Bendamustin
Chemotherapy
• Obinutuzumab
Immunotherapy

Locations

Country	Name	City	State
Israel	Meir medical center	Kfar Saba

Sponsors (5)

Lead Sponsor	Collaborator
Meir Medical Center	Assuta Ashdod Hospital, Rabin Medical Center, Tel-Aviv Sourasky Medical Center, Ziv Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression free survival among patients treated with 4 cycles of BO & 2 additional cycles of obinutuzumab.	Progression-free survival is defined as the time from randomization to the earliest event of progression, relapse, or death from any cause. progression-free survival, is assessed by the investigator.	Progression free survival will be assessed 24 months after the end of induction.
Secondary	Progression of disease within 24 months (POD24)	POD24 is defined as disease progression or death due to disease progression occurring within 24 months after treatment initiation, as assessed by the investigator.	POD24 will be assessed at 24 months after treatment initiation
Secondary	Overall survival among patients treated with 4 cycles of BO & 2 additional cycles of obinutuzumab.	Overall survival is defined as the time from study initiation to death from any cause.	Overall survival will be assessed 24 months after the end of induction.
Secondary	The rate of MRD negativity persistence at 12 months among patients treated with 4 cycles of BO & 2 additional cycles of obinutuzumab.	MRD will be assessed at mid-induction, end of induction and subsequently every 6 months.	Persistence of MRD negativity will be assessed 12 months after study initiation.
Secondary	The proportion of adverse events among patients treated with 4 cycles of BO & 2 additional cycles of obinutuzumab.	The proportion of various adverse events will be assessed as documented by the investigator.	The proportion of various adverse events will be assessed until 24 months from the end of induction.